Tebon Securities·2025-11-25 09:46Market Overview - The major indices experienced significant declines, with the Shanghai Composite Index down 3.90%, the Shenzhen Component down 5.13%, and the ChiNext Index down 6.15% during the week of November 17-21, 2025[6] - The average daily trading volume decreased to 1.87 trillion yuan, down from 2.04 trillion yuan the previous week[6] E-commerce in Southeast Asia - The e-commerce market in Southeast Asia is evolving towards a more mature and compliant structure, with a projected GMV of $128.4 billion in 2024, reflecting a 12% year-on-year growth[16] - Indonesia remains the largest market, accounting for 44% of the total GMV in Southeast Asia, although its growth rate slowed to 5% in 2024[17] - Content-driven e-commerce is emerging as a key growth driver, with live-streaming e-commerce expected to reach $17.6 billion in GMV, representing 14% of the total e-commerce market in the region[27] High-end Manufacturing: Power Batteries - Global demand for power batteries is expected to exceed 1 TWh in 2024, with electric vehicles contributing over 85% of this demand, reaching 950 GWh, a 25% increase year-on-year[29] - China's power battery production capacity is projected to grow by 41.49% in 2025, reaching 548.5 GWh, aligning closely with the sales of new energy vehicles[35] - The industry is transitioning from rapid expansion to a focus on quality and technological upgrades, driven by stricter regulations and self-discipline among leading companies[40] Hard Technology: Storage Prices - Storage prices are on the rise, with DDR4 and DDR5 prices increasing by 158% and 307% respectively since September 2025, leading to a contraction in transaction volumes[41] - The anticipated increase in smartphone and laptop costs due to rising storage prices is estimated to be around 5-7% in 2026, with potential impacts on demand[42] Health Sector: Small Nucleic Acids - The global market for RNAi therapies is projected to grow from $3.459 billion in 2024 to $25.195 billion by 2030, with a CAGR of 39.2%[49] - Over 20 small nucleic acid drugs have been approved globally, with nearly 170 projects in clinical stages, indicating a robust pipeline in oncology and chronic disease treatment[49]